Taking On Challenges And Growing? – Coherus Biosciences Inc (CHRS)

After Hours

There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Most recently, Yahoo Finance reported about the stock as it publicized that Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

Stocks Info

This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. At the end of the last regular session, the stock closed at $2.82 and fluctuated between $2.8400 as its day high and $2.5725 as its day low. The current market capitalization of Coherus Biosciences Inc is $314.04M. A total of 3.24 million shares were traded on the day, compared to an average of 0.49 shares.

Insider trades can also provide insight into a stock’s future direction. During the recent three months, CHRS has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 0 BUYs and 3 SELLs from insiders. Insiders purchased 0 shares during that period but sold 22,186.

In the most recent transaction, Lanfear Dennis M sold 223,100 shares of CHRS for 2.02 per share on Nov 22. After the transaction, the President & CEO now owns 731,693 company shares.

Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. According to analysts who have offered 12-month price targets for CHRS in the last 3 months, the mean price target is $11.67 with high estimates of $23.00 and low estimates of $7.00. In terms of 52-week highs and lows, CHRS has a high of $8.65 and a low of $1.43.

As of this writing, CHRS has an earnings estimate of $Cerus Corporation per share for the current quarter. EPS was calculated based on a consensus of Coherus BioSciences, Inc. estimates, with a high estimate of $C.H. Robinson Worldwide, Inc. per share and a lower estimate of $Chord Energy Corporation.

Balance Sheet Annually/Quarterly

In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. CHRS’s latest balance sheet shows that the firm has $417.19M in Cash & Short Term Investments as of fiscal 2021. There were $419.02M in debt and $165.33M in liabilities at the time. Its Book Value Per Share was -$1.22, while its Total Shareholder’s Equity was $97.73M.

Analysts Opinion

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for CHRS is Buy with a score of 4.40.

Most Popular

Related Posts